Antihypertensive therapy

Centrally acting agents in clinical practice

In modern medical practice, centrally acting antihypertensive agents play an important role. The choice of a specific drug depends on the clinical situation, the need for a rapid or prolonged effect, and the presence of concomitant metabolic disorders in the patient.

• Clonidine is a potent short-acting drug. Its main clinical niche is the emergency management of hypertensive crises. The use of clonidine for systematic therapy of arterial hypertension is currently significantly limited. This is due to the high risk of adverse side effects with long-term regular administration.
• Guanfacine, in contrast, is intended specifically for systematic, so-called baseline therapy of arterial hypertension. This drug is considered the preferred choice in cases where the patient requires long-term and continuous treatment. The convenience of guanfacine is that it only needs to be taken once a day, which significantly improves patient adherence to the prescribed therapy.
• Moxonidine is also used for baseline therapy, but has specific indications. According to the results of the ALMAZ clinical study, moxonidine is particularly indicated for patients in whom mild arterial hypertension is combined with overweight, signs of insulin resistance, and various carbohydrate metabolism disorders. It is important to note that prescribing this drug in the early stages of therapy requires strict clinical justification by the attending physician.

Adrenoceptor blockers and principles of combination therapy

The group of alpha- and beta-adrenoceptor blockers has a wide range of therapeutic applications. These drugs can be prescribed both as monotherapy and as part of complex combination treatment regimens.

The main indications for prescribing adrenoceptor blockers include:

1. Arterial hypertension of various severity grades.
2. Coronary artery disease (CAD).
3. Tachyarrhythmias (in this case, predominantly beta-adrenoceptor blockers are used).
4. Chronic heart failure (only specific, strictly defined representatives of the beta-blocker group are used to treat this pathology).

An important principle of treatment is that all neurotropic antihypertensive agents are very frequently prescribed in combination with diuretics. This tactic pursues two main goals: first, potentiation (enhancement) of the overall hypotensive effect, and second, reliable prevention of fluid retention in the patient's body.

If target blood pressure values cannot be achieved and hypertension corrected against the background of monotherapy, the treatment regimen is expanded. The level of evidence for these recommendations is rated as C (5). As additional agents (ATC code C02), preference is given to potassium-sparing diuretics (ATC code C03D). Selective calcium channel blockers that are dihydropyridine derivatives (ATC code C08CA) can also be successfully used.

Prophylactic treatment of migraine

An interesting and important aspect of using antihypertensive agents is their use outside of direct cardiological indications — in particular, for the prophylaxis of migraine attacks. This group includes drugs that were originally developed to treat completely different pathologies, but during clinical observations demonstrated a proven antimigraine effect.

Indications for prescribing such specific therapy are very frequent or extremely severe migraine attacks, as well as low clinical efficacy of standard drugs used to relieve acute pain.

The principles of prophylactic migraine therapy differ radically from the relief of acute attacks:

• Dosage regimen: Drugs must be taken strictly daily, unlike agents used only at the time of an attack.
• Treatment goal: Complete prevention of the development of new attacks, rather than relieving an already occurred pain syndrome.
• Course duration: Treatment is long-term and ranges from 3 to 12 months. On average, the course lasts about 6 months; the exact duration depends on the severity of the disease in a particular patient.
• Compliance: Strict adherence to the intake regimen is critically important. The main reason for the insufficient efficacy of prophylaxis lies precisely in patient non-adherence.

In addition to antihypertensive agents, antidepressants and antiepileptic drugs (anticonvulsants) are successfully used for migraine prophylaxis. It is fundamentally important to understand that these medications are prescribed to the patient regardless of whether they suffer from depression, epilepsy, or hypertension.

Class and exam questions

What else to study on this topic

• Pharmacodynamics of alpha- and beta-adrenoceptor blockers in the treatment of chronic heart failure.
• Mechanism of action of potassium-sparing diuretics (ATC code C03D).
• Features of the use of dihydropyridine calcium channel blockers (ATC code C08CA).
• Detailed results of the ALMAZ clinical study in the treatment with moxonidine.
• Use of antidepressants and anticonvulsants in complex migraine prophylaxis.

Other topics in the "Additional Topics" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.